Docetaxel or Paclitaxel

Phase 3Small molecule

SSichuan Baili Pharmaceutical Co., Ltd.

Docetaxel or Paclitaxel is one of 74 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Urothelial CarcinomaActive, not recruiting

Breast CancerPhase 3

Active, not recruiting

Urothelial CarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tykerb

GSK

Preclinical

80 2

Docetaxel or Paclitaxel

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

1 3

MS Contin

Merck & Co.

Preclinical

2 4

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 8

Tricor

JJagotec

Preclinical

1 9

Chantix

PPrism Pharmaceuticals

Preclinical

1 10

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Urothelial Carcinoma

NCT06857175

Q3 2030

Phase 3Recruiting

Breast Cancer

NCT04540692

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer

Recruiting·LLatin American Cooperative Oncology Group·Phase 3·NCT04540692·444 enrolled

Urothelial Carcinoma1 trial

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 3·NCT06857175·508 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Docetaxel or Paclitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Docetaxel or Paclitaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Docetaxel or Paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan Baili Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSichuan Baili Pharmaceutical Co., Ltd.

Docetaxel or Paclitaxel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2030

Trials by Indication[1]

Breast Cancer1 trial

Urothelial Carcinoma1 trial

References

Drug Info

Quick Facts

Related News